Home/Pipeline/GH003

GH003

Not Specified

DevelopmentPreclinical/Formulation

Key Facts

Indication

Not Specified

Phase

Development

Status

Preclinical/Formulation

Company

GH Research

About GH Research

GH Research is an Irish biotech company founded in 2018 with a mission to revolutionize the treatment of severe psychiatric disorders through its innovative mebufotenin-based platform. Its core achievement is the development of the Individualized Dosing Regimen (IDR), which has demonstrated high remission rates in early trials for treatment-resistant depression. The company's strategy is to advance its lead inhaled formulation, GH001, through late-stage clinical development for multiple indications, leveraging its strong intellectual property portfolio and aiming to address a massive unmet need with a potentially paradigm-shifting therapy.

View full company profile

Therapeutic Areas

Psychiatry Neurology

Other Not Specified Drugs

Drug	Company	Phase	Status
New TCM Formulations	China SXT Pharmaceuticals	Research / Pre-clinical	Development
Long-acting Leronlimab	CytoDyn	Preclinical	Phase in progress
Collaborative Program with Ferring	PharmaBiome	Research	Active
Lighthouse Pilot Product	Cipherome	Pilot	Launched 2020
Nitric Oxide + Collagen Delivery	Jellagen	Research	Active
Undisclosed	Authera	Pre-clinical	Active
mRNA Therapeutics Platform Application	Lupagen	Research	Active
PHYRAGO	Handa Pharmaceuticals	Approved	Active
TASCENSO ODT	Handa Pharmaceuticals	Approved	Active
Axulin	Housey Pharmaceutical Research Laboratories	Commercial	Active
PBI-04711	Phoenix Biotechnology	Pre-clinical	Active
Immunology Program	Ignite Biomedical	Discovery	Active